Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DELOS Nanovesicles-Based Hydrogels: An Advanced Formulation for Topical Use

  • Ballell Hosa, Lídia
  • González Mira, Elisabet
  • Santana, Hector
  • Morla Folch, Judit
  • Moreno Masip, Marc
  • Martínez Prieto, Yaima
  • Revuelta, Albert
  • Mauro, Primiano Pio Di
  • Veciana, Jaume
  • Sala Vergés, Santiago
  • Ferrer Tasies, Lidia P.
  • Ventosa, Nora
Topical delivery has received great attention due to its localized drug delivery, its patient compliance, and its low risk for side effects. Recent developments have focused on studying new drug delivery systems as a strategy for addressing the challenges of current topical treatments. Here we describe the advances on an innovative drug delivery platform called DELOS nanovesicles for topical drug delivery. Previously, the production of DELOS nanovesicles demonstrated potentiality for the topical treatment of complex wounds, achieving well-tolerated liquid dispersions by this route. Here, research efforts have been focused on designing these nanocarriers with the best skin tolerability to be applied even to damaged skin, and on exploring the feasibility of adapting the colloidal dispersions to a more suitable dosage form for topical application. Accordingly, these drug delivery systems have been efficiently evolved to a hydrogel using MethocelTM K4M, presenting proper stability and rheological properties. Further, the integrity of these nanocarriers when being gellified has been confirmed by cryo-transmission electron microscopy and by Förster resonance energy transfer analysis with fluorescent-labeled DELOS nanovesicles, which is a crucial characterization not widely reported in the literature. Additionally, in vitro experiments have shown that recombinant human Epidermal Growth Factor (rhEGF) protein integrated into gellified DELOS nanovesicles exhibits an enhanced bioactivity compared to the liquid form. Therefore, these studies suggest that such a drug delivery system is maintained unaltered when hydrogellified, becoming the DELOS nanovesicles-based hydrogels, an advanced formulation for topical use., This research was funded by Industrial Doctorates Plan of Agaur-Generalitat de Catalunya (2018 DI 057). This work was also co-financed by European Regional Development Funds from the European Union within the framework of the operative FEDER program in Catalonia 2014–2020, by the specific project NANONAFRES (COMRDI15-1-0023). We thank the Spanish Ministry of Science and Innovation (MICINN) for financing MOL4BIO project through grant No. PID2019-105622RB-I00. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 953110. ICMAB-CSIC members acknowledge support from the MINECO through the Severo Ochoa Program for Centers of Excellence in R&D (SEV-2015-0496 and CEX2019-000917-S), and through the State Program for R&D&i (2016), orientated to the Society Challenges, modality RETOS-Collaboration 2016, and co-financed by FEDER funds from the European Commission (grant No. RTC-2016-4567-1, Nano4Derm). ICMAB-CSIC members also thank Agaur agency of Generalitat de Catalunya for their support through grant No. 2017-SGR-918. DELOS nanovesicle production and their physicochemical characterization was performed by the ICTS “NANBIOSIS”, more specifically in the Biomaterial Processing and Nanostructuring Unit (U6), Unit of the CIBER in Bioengineering, Biomaterials and Nanomedicne (CIBER-BBN) located at the Institute of Materials Science of Barcelona (ICMAB-CSIC). This work has been done in the framework of the L.B.-H. doctorate in Materials Science of the Universitat Autonoma de Barcelona., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hierarchical Quatsome-RGD Nanoarchitectonic Surfaces for Enhanced Integrin-Mediated Cell Adhesion

  • Martínez Miguel, Marc
  • Castellote Borrell, Miquel
  • Köber, Mariana
  • Kyvik Ruiz, Adriana
  • Tomsen Melero, Judit
  • Vargas Nadal, Guillem
  • Muñoz Martín, José M.
  • Pulido, Daniel
  • Cristóbal Lecina, Edgar
  • Passemard, Solène
  • Royo, Miriam
  • Mas Torrent, Marta
  • Veciana, Jaume
  • Giannotti, Marina I.
  • Guasch, Judit
  • Ventosa, Nora
  • Ratera, Immaculada
The synthesis and study of the tripeptide Arg-Gly-Asp (RGD), the binding site of different extracellular matrix proteins, e.g., fibronectin and vitronectin, has allowed the production of a wide range of cell adhesive surfaces. Although the surface density and spacing of the RGD peptide at the nanoscale have already shown a significant influence on cell adhesion, the impact of its hierarchical nanostructure is still rather unexplored. Accordingly, a versatile colloidal system named quatsomes, based on fluid nanovesicles formed by the self-assembling of cholesterol and surfactant molecules, has been devised as a novel template to achieve hierarchical nanostructures of the RGD peptide. To this end, RGD was anchored on the vesicle's fluid membrane of quatsomes, and the RGD-functionalized nanovesicles were covalently anchored to planar gold surfaces, forming a state of quasi-suspension, through a long poly(ethylene glycol) (PEG) chain with a thiol termination. An underlying self-assembled monolayer (SAM) of a shorter PEG was introduced for vesicle stabilization and to avoid unspecific cell adhesion. In comparison with substrates featuring a homogeneous distribution of RGD peptides, the resulting hierarchical nanoarchitectonic dramatically enhanced cell adhesion, despite lower overall RGD molecules on the surface. The new versatile platform was thoroughly characterized using a multitechnique approach, proving its enhanced performance. These findings open new methods for the hierarchical immobilization of biomolecules on surfaces using quatsomes as a robust and novel tissue engineering strategy., This work was supported by MICINN (PID2019-105622RBI00, MAT2016-80826-R, PID2019-111682RB-I00, PID2020-115296RA-I00, CTQ2015-66194-R; SAF2014-60138-R, RTI2018-093831-B-I00, and PDC2021-121481-I00); Instituto de Salud Carlos III (ISCIII) through the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN (FlexQS-skin, FlexCAB, BBN18PI01, BBN20PIV02, and CB/06/0074); Generalitat de Catalunya (grants 2017-SGR-918, 2017-SGR-229, 2017-SGR-1442, 2017-SGR-1439); the Fundació Marató de TV3 (Nr. 201812); the COST Action CA15126 Between Atom and Cell, and “ERDF A way of making Europe”. J.G. acknowledges financial support from the Ramón y Cajal Program (RYC-2017-22614) from MICINN and the Max Planck Society through the Max Planck Partner Group “Dynamic Biomimetics for Cancer Immunotherapy” in collaboration with the Max Planck Institute for Medical Research (Heidelberg, Germany). This work has received funding from the European Union’s Horizon 2020 research and innovation program through grant agreements 953110 (PHOENIX), 720942 (Smart4Fabry), 101007804 (MICRO4NANO), and 801342 (granted to the Agency for Business Competitiveness ACCIÓ through a Tecniospring Industry fellowship (TECSPR19-1-0065)). ICMAB acknowledges support from MICINN through the “‘Severo Ochoa”’ Programme for Centres of Excellence in R&D (CEX2019-000917-S). J.M. acknowledges a “Juan de la Cierva” fellowship from MICINN. J.T-M. acknowledges an FI-AGAUR grant (2020FI_B2 00137) from Generalitat de Catalunya and the European Social Fund. We also acknowledge the ICTS “NANBIOSIS for the support of the Synthesis of Peptides Unit (U3) at IQAC–CSIC (https://www.nanbiosis.es/portfolio/u3-synthesis-of-peptides-unit/) and the Biomaterial Processing and Nanostructuring Unit (U6) at ICMAB-CSIC (https://www.nanbiosis.es/portfolio/u6-biomaterial-processing-and-nanostructuring-unit/). We are grateful to the SMP unit of the Scientific and Technological Centers of University of Barcelona (CCiTUB). This work has been developed under the “Biochemistry, Molecular Biology and Biomedicine” and “Materials Science” Ph.D. programs of Universitat Autònoma de Barcelona (UAB)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Liposomal formulations for treating lysosomal storage disorders

  • Tomsen Melero, Judit
  • Merlo Mas, Josep
  • Carreño, Aida
  • Sala Vergés, Santiago
  • Córdoba, Alba
  • Veciana, Jaume
  • González Mira, Elisabet
  • Ventosa, Nora
Lysosomal storage disorders (LSD) are a group of rare life-threatening diseases caused by a lysosomal dysfunction, usually due to the lack of a single enzyme required for the metabolism of macromolecules, which leads to a lysosomal accumulation of specific substrates, resulting in severe disease manifestations and early death. There is currently no definitive cure for LSD, and despite the approval of certain therapies, their effectiveness is limited. Therefore, an appropriate nanocarrier could help improve the efficacy of some of these therapies. Liposomes show excellent properties as drug carriers, because they can entrap active therapeutic compounds offering protection, biocompatibility, and selectivity. Here, we discuss the potential of liposomes for LSD treatment and conduct a detailed analysis of promising liposomal formulations still in the preclinical development stage from various perspectives, including treatment strategy, manufacturing, characterization, and future directions for implementing liposomal formulations for LSD., This work has received funding from: Grant Severo Ochoa CEX2019-000917-S funded by Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación MCIN/AEI/10.13039/501100011033; Project MOL4BIO PID2019-105622RB-I00 funded by Agencia Estatal de Investigación - Ministerio de Ciencia e Innovación MCIN/AEI/10.13039/501100011033; Project PHOENIX-OITB funded by European Union’s Horizon 2020 research and innovation programme under grant agreement No 953110; Project SMART4FABRY funded by European Union’s Horizon 2020 research and innovation programme under grant agreement No 720942. The authors are also grateful to the Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Stable nanovesicles formed by intrinsically planar bilayers

  • Köber, Mariana
  • Illa Tuset, Silvia
  • Ferrer Tasies, Lidia P.
  • Moreno Calvo, Evelyn
  • Tatkiewicz, Witold I.
  • Grimaldi, Natascia
  • Piña, David
  • Pérez Pérez, Alejandro
  • Lloveras, Vega
  • Vidal Gancedo, José
  • Bulone, Donatella
  • Ratera, Immaculada
  • Pedersen, Jan Skov
  • Danino, Dganit
  • Veciana, Jaume
  • Faraudo, Jordi
  • Ventosa, Nora
Quatsome nanovesicles, formed through the self-assembly of cholesterol (CHOL) and cetyltrimethylammonium bromide (CTAB) in water, have shown long-term stability in terms of size and morphology, while at the same time exhibiting high CHOL-CTAB intermolecular binding energies. We hypothesize that CHOL/CTAB quatsomes are indeed thermodynamically stable nanovesicles, and investigate the mechanism underlying their formation., This work was supported by funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 712949 (TECNIOspring PLUS) and from the Agency for Business Competitiveness of the Government of Catalonia. The production of quatsomes and part of their characterization has been performed by the ICTS “NANBIOSIS”, more specifically by the Biomaterial Processing and Nanostructuring Unit (U6), Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN) located at the Institute of Materials Science of Barcelona (ICMAB-CSIC). ICMAB-CSIC acknowledges support from the MINECO through the Severo Ochoa Programme for Centres of Excellence in R&D (SEV-2015-0496 and CEX2019-000917-S). Authors acknowledge financial support from the Spanish Ministry of Science and Innovation through grants “MOL4BIO” (PID2019-105622RB-I00), “SimBioSoft” (PID2021-124297NB-C33) and the FUNFUTURE-FIP-2020 Severo Ochoa project, from Generalitat de Catalunya through grant 2017-SGR-918, from CSIC through grant 2019AEP133, and from the European Commission through the H2020 PHOENIX project (contract no. 953110). We acknowledge the support of the Israel scienceIsrael science Foundation, grant 1117/2016, and thank Dr. Inbal Ionita for her professional assistance in the cryo-TEM analysis. We thank Jannik Nedergaard Pedersen and Beatrice Plazzotta for help with the SAXS measurements. The simulations reported here were performed using the Cori Supercomputing facility of the National Energy Research Scientific Computing Center (NERSC), a U.S. Department of Energy Office of Science User Facility operated under Contract No. DE-AC02-05CH11231., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2019-000917-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease

  • Tomsen-Melero, Judit
  • Moltó-Abad, Marc
  • Merlo-Mas, Josep
  • Díaz-Riascos, Zamira V.
  • Cristóbal-Lecina, Edgar
  • Soldevila, Andreu
  • Altendorfer-Kroath, Thomas
  • Danino, Dganit
  • Ionita, Inbal
  • Pedersen, Jan Skov
  • Snelling, Lyndsey
  • Clay, Hazel
  • Carreño, Aida
  • Corchero, José L.
  • Pulido, Daniel
  • Casas, Josefina
  • Veciana, Jaume
  • Schwartz, Simó
  • Sala, Santi
  • Font, Albert
  • Birngruber, Thomas
  • Royo, Miriam
  • Córdoba, Alba
  • Ventosa, Nora
  • Abasolo, Ibane
  • González-Mira, Elisabet
The central nervous system represents a major target tissue for therapeutic approach of numerous lysosomal storage disorders. Fabry disease arises from the lack or dysfunction of the lysosomal alpha-galactosidase A (GLA) enzyme, resulting in substrate accumulation and multisystemic clinical manifestations. Current enzyme replacement therapies (ERTs) face limited effectiveness due to poor enzyme biodistribution in target tissues and inability to reach the brain. We present an innovative drug delivery strategy centered on a peptide-targeted nanoliposomal formulation, designated as nanoGLA, engineered to selectively deliver a recombinant human GLA (rhGLA) to target tissues. In a Fabry mouse model, nanoGLA demonstrated improved efficacy, inducing a notable reduction in Gb3 deposits in contrast to non-nanoformulated GLA, even in the brain, highlighting the potential of the nanoGLA to address both systemic and cerebrovascular manifestations of Fabry disease. The EMA has granted the Orphan Drug Designation to this product, underscoring the potential clinical superiority of nanoGLA over authorized ERTs and encouraging to advance it toward clinical translation., This work was supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 720942 (SMART4FABRY); the European Union’s Horizon 2020 research and innovation programme 953110 PHOENIX-OITB (to J.T.-M., J.M.-M., A.S., A.Ca., A.F., S.Sa., A.Có., N.V., and E.G.-M.); European Union EIC Transition, 101136772 Nano4Rare (to J.T.-M., A.Ca., N.V., and E.G.-M.); the Generalitat de Catalunya, FI-AGAUR, Secretary of Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya and the European Social Fund (ESF–Investing in your future) of the European Union (to J.T.-M.); CIBER-BBN, EXPLORE-3, and PEGLyso-2 project (to I.A.); the Instituto de Salud Carlos III grants PI18/00871 and PI21/00936, cofounded by European Regional Development Fund (to I.A.); Catalan Government’s Strategic Plan for Research and Innovation in Health, PERIS, SLT01720000181 (to M.M.-A.); the Generalitat de Catalunya, 2017 SGR 1439 and 2021 SGR 00230 (to E.C.-L., D.P., and M.R.), 2021 SGR 1173 (to I.A.), and 2021 SGR 00438 (to J.T.-M., A.Ca., J.V., N.V., and E.G.-M.); Generalitat de Catalunya, AGAUR, 2021 INNOV 00053 (to J.T.-M., A.Ca., N.V., and E.G.-M.); the Ministerio de Ciencia e Innovación, Plan Estatal de Investigación Científica y Técnica y de Innovación (PEICTI) 2021–2023, PID2022-137332OB-I00 (ARMONIA) (to J.T.-M., A.Ca., N.V., and E.G.-M.); and the Ministerio de Ciencia e Innovación, Severo Ochoa Programme, CEX2019-000917-S (FUNFUTURE) and CEX2023-001263-S (to J.T.-M., A.Ca., N.V., and E.G.-M.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

P22-44 Estrogenic activity of nanoplastics in vitro

  • Peranić, N.
  • Božičević, L.
  • Altmann, K.
  • Hildebrandt, J.
  • Portela, Raquel
  • Bañares, Miguel A.
  • Vinković Vrček, I.
The large-scale production of plastic items, their endurance, and inadequate recycling practices have led to massive plastic pollution. [1] Degradation of larger plastic items through mechanical, biological, or chemical processes can lead to the formation of nanoplastics, particles characterized by small size and large surface area. Due to those properties, nanoplastics can penetrate different biological barriers, posing potential risk for different organisms. Humans are continuously exposed to plastics through multiple environmental and consumer-related pathways, while the consequences for human health are still being investigated. [2] Since the endocrine system regulates many biological functions and plays a key role in the development of many diseases, it is crucial to examine the effect of nanoplastics on its function. This study investigates toxicity and endocrine disrupting potential of 8 different plastic nanoparticles (PNPs) and their mixtures using cell line HeLa-9903, designed to assess the effects of various chemicals on the estrogen receptor (ER) activity. To explore the influence of polymer type and nanoparticle size on their ability to interact with ER, we used 4 different polymers and 5 different sizes. Polystyrene nanoparticles (PSNPs, 50 nm, 150 nm, 350 nm), polyethylene nanoparticles (PENPs, 50 nm, 350 nm), polypropylene nanoparticles (PPNPs, 50 nm, 180 nm) and polyethylene terephthalate nanoparticles (PETNPs, 80 nm) were included in this research. Four different PNPs mixtures were evaluated: MIX50 (PSNPs 50 nm, PENPs 50 nm, PPNPs 50 nm and PET), MIX150 (PSNPs 150 nm and PPNPs 180 nm), MIX350 (PSNPs 350 nm and PENPs 350 nm) and MIXPS (PSNPs 50 nm, 150 nm and 350 nm). MTS assay was used to evaluate the cytotoxicity of PNPs individually and in mixtures, while only non-toxic combinations were tested for their interaction with ER, according to the OECD test guideline No. 455. [3] Results showed that PENPs (350 nm) and PPNPs (180 nm) individually act as ER agonists. The same effect was observed with all mixtures except the one with 3 differently sized PSNPs. As PSNPs did not exhibit agonistic activity regardless of their size, the findings of this study suggest that polymer type has a more significant influence on endocrine activity than nanoparticle size., This study was performed using the facilities and equipment funded as part of the European Regional Development Fund project KK.01.1.1.02.0007 and the European Union – Next Generation EU programme (contract document designation 643-02/23-01/00016) and financed within EU H2020 project “PHOENIX” funded under grant agreement no. 953110, Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Plasmid DNA Delivery Using a Stable Nanovesicle Platform: A Design-of-Experiments-Guided Investigation

  • González-Domínguez, Irene
  • Valdospinos, Diego
  • Puente-Massaguer, Eduard
  • Piqué-Ponti, Júlia
  • Piña, David
  • Köber, Mariana
  • Boloix, Ariadna
  • Segura, Miguel F.
Design of Experiments; HEK293 cell transfection; Green fluorescent protein, Disseny d'experiments; Transfecció de cèl·lules HEK293; Proteïna fluorescent verda, Diseño de experimentos; Transfección de células HEK293; Proteína fluorescente verde, Delivering plasmid DNA (pDNA) into cells is essential for numerous biotechnological and biomedical applications. Among available nanocarriers, nonviral lipid-based vesicles are particularly promising for transfecting mammalian cells. Nevertheless, further development is required to create delivery systems that are both broadly effective across cell types and scalable for clinical use. Here, we explore stable nanovesicles composed of the sterol derivative cholesteryl N-(2-dimethylaminoethyl)carbamate (DC-CHOL) and myristalkonium chloride (MKC) as a platform for pDNA delivery. These nanovesicles, previously shown to efficiently deliver small RNAs to neuroblastoma cells, exhibit favorable physicochemical properties, such as high morphological uniformity and long-term colloidal stability, positioning them as strong candidates for DNA transfection. Using suspension-adapted human embryonic kidney 293 (HEK293) cells, which are widely employed for producing viral vectors and complex biotherapeutics, we evaluated the delivery performance of DC-CHOL/MKC nanovesicles with a reporter plasmid encoding enhanced green fluorescent protein. A Design of Experiments (DoE) approach was applied to identify and optimize critical transfection parameters, namely, the DNA concentration, DNA-to-vesicle ratio, and NaCl concentration in the complexing medium. This study demonstrates the capability of these nonviral vectors to deliver double-stranded plasmid DNA and emphasizes the critical role of the physicochemical characteristics of the pDNA/lipid complex in achieving efficient transfection., This research was supported by funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 712949 (TECNIOspring PLUS) and from the Agency for Business Competitiveness of the Government of Catalonia. I.G.-D. (FPU16/02555) and E.P.-M. (FPU15/03577) were recipients of FPU grants from the Ministry of Education, Culture and Sport of Spain. The authors acknowledge financial support from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 953110 (PHOENIX-OITB project); from the Spanish Ministry of Science and Innovation through grant PID2022-137332OB-I00 (projects ARMONIA) and the Severo Ochoa Program for Centers of Excellence in R&D (CEX2019-000917-S, CEX2023-001263-S); from Instituto de Salud Carlos III through the CIBER─Consorcio Centro de Investigación Biomédica en Red (group CB06/01/0033), and (PI23/01144, ICI21000/76, FORT23/00034, cofunded by the European Regional Development Fund/European Social Fund; “A way to make Europe”/“Investing in your future”); and from Generalitat de Catalunya through grants 2021-SGR-00438 and 2021-SGR-00638. The production of quatsomes and part of their characterization have been performed by the ICTS “NANBIOSIS”, more specifically by the Biomaterial Processing and Nanostructuring Unit (U6), Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN) located at the Institute of Materials Science of Barcelona (ICMAB-CSIC). The authors would like to thank Jamila Djafari for support with the graphical illustrations.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Plasmid DNA Delivery Using a Stable Nanovesicle Platform: A Design-of-Experiments-Guided Investigation

  • González-Domínguez, Irene
  • Valdospinos, Diego
  • Puente-Massaguer, Eduard
  • Piqué-Ponti, Júlia
  • Piña, David
  • Köber, Mariana
  • Boloix, Ariadna
  • Segura, Miguel F.
Design of Experiments; HEK293 cell transfection; Green fluorescent protein, Disseny d'experiments; Transfecció de cèl·lules HEK293; Proteïna fluorescent verda, Diseño de experimentos; Transfección de células HEK293; Proteína fluorescente verde, Delivering plasmid DNA (pDNA) into cells is essential for numerous biotechnological and biomedical applications. Among available nanocarriers, nonviral lipid-based vesicles are particularly promising for transfecting mammalian cells. Nevertheless, further development is required to create delivery systems that are both broadly effective across cell types and scalable for clinical use. Here, we explore stable nanovesicles composed of the sterol derivative cholesteryl N-(2-dimethylaminoethyl)carbamate (DC-CHOL) and myristalkonium chloride (MKC) as a platform for pDNA delivery. These nanovesicles, previously shown to efficiently deliver small RNAs to neuroblastoma cells, exhibit favorable physicochemical properties, such as high morphological uniformity and long-term colloidal stability, positioning them as strong candidates for DNA transfection. Using suspension-adapted human embryonic kidney 293 (HEK293) cells, which are widely employed for producing viral vectors and complex biotherapeutics, we evaluated the delivery performance of DC-CHOL/MKC nanovesicles with a reporter plasmid encoding enhanced green fluorescent protein. A Design of Experiments (DoE) approach was applied to identify and optimize critical transfection parameters, namely, the DNA concentration, DNA-to-vesicle ratio, and NaCl concentration in the complexing medium. This study demonstrates the capability of these nonviral vectors to deliver double-stranded plasmid DNA and emphasizes the critical role of the physicochemical characteristics of the pDNA/lipid complex in achieving efficient transfection., This research was supported by funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 712949 (TECNIOspring PLUS) and from the Agency for Business Competitiveness of the Government of Catalonia. I.G.-D. (FPU16/02555) and E.P.-M. (FPU15/03577) were recipients of FPU grants from the Ministry of Education, Culture and Sport of Spain. The authors acknowledge financial support from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 953110 (PHOENIX-OITB project); from the Spanish Ministry of Science and Innovation through grant PID2022-137332OB-I00 (projects ARMONIA) and the Severo Ochoa Program for Centers of Excellence in R&D (CEX2019-000917-S, CEX2023-001263-S); from Instituto de Salud Carlos III through the CIBER─Consorcio Centro de Investigación Biomédica en Red (group CB06/01/0033), and (PI23/01144, ICI21000/76, FORT23/00034, cofunded by the European Regional Development Fund/European Social Fund; “A way to make Europe”/“Investing in your future”); and from Generalitat de Catalunya through grants 2021-SGR-00438 and 2021-SGR-00638. The production of quatsomes and part of their characterization have been performed by the ICTS “NANBIOSIS”, more specifically by the Biomaterial Processing and Nanostructuring Unit (U6), Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN) located at the Institute of Materials Science of Barcelona (ICMAB-CSIC). The authors would like to thank Jamila Djafari for support with the graphical illustrations.